We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.01B
AUM Growth
+$262M
Cap. Flow
-$162M
Cap. Flow %
-2.7%
Top 10 Hldgs %
51.52%
Holding
592
New
224
Increased
125
Reduced
42
Closed
159

Top Buys

Rank Stock Value
1
WAY
Waystar Holding Corp
WAY
+$107M
2
GILD icon
Gilead Sciences
GILD
+$99.5M
3
CVS icon
CVS Health
CVS
+$61M
4
BAX icon
Baxter International
BAX
+$57.9M
5
CGEM icon
Cullinan Oncology
CGEM
+$45.6M

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$136M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$80.7M
3
SWTX
SpringWorks Therapeutics
SWTX
+$63.2M
4
OSCR icon
Oscar Health
OSCR
+$44.4M
5
VKTX icon
Viking Therapeutics
VKTX
+$38M

Sector Composition

Rank Sector Weight
1 Healthcare 83.29%
2 Industrials 0.69%
3 Technology 0.57%
4 Financials 0.44%
5 Consumer Discretionary 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
26
BioNTech
BNTX
$23.1B
$47.7M 0.79%
594,000
+24,426
+4% +$2.23M
IRON icon
27
Disc Medicine
IRON
$2.91B
$46.1M 0.77%
1,023,265
+357,730
+54% +$12.2M
EHAB
28
DELISTED
Enhabit
EHAB
$44.6M 0.74%
4,997,746
– –
CNMD icon
29
CONMED
CNMD
$1.3B
$43.8M 0.73%
631,264
+293,099
+87% +$21.4M
IART icon
30
Integra LifeSciences
IART
$1.5B
$42.8M 0.71%
1,467,632
-5,458
-0.4% -$162K
BIO icon
31
Bio-Rad Laboratories Class A
BIO
$8.15B
$41.4M 0.69%
151,714
-664
-0.4% -$193K
DAWN
32
DELISTED
Day One Biopharmaceuticals
DAWN
$40.3M 0.67%
2,923,137
+1,157,825
+66% +$16.9M
LKFT
33
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
$35M 0.58%
1,411,000
– –
EMBC icon
34
Embecta
EMBC
$193M
$34.1M 0.57%
2,726,135
– –
GPCR icon
35
Structure Therapeutics
GPCR
$3.45B
$33.2M 0.55%
844,407
-189,273
-18% -$7.77M
COGT icon
36
Cogent Biosciences
COGT
$6.68B
$31.6M 0.53%
3,744,263
+2,209,918
+144% +$16.8M
ALNY icon
37
Alnylam Pharmaceuticals
ALNY
$35.7B
$29.1M 0.48%
+119,800
New +$18.9M
CATX icon
38
Perspective Therapeutics
CATX
$341M
$28.1M 0.47%
2,817,763
-1
-0% -$14
PHVS icon
39
Pharvaris
PHVS
$2.44B
$26.3M 0.44%
1,397,279
+335,687
+32% +$6.83M
MREO
40
Mereo BioPharma
MREO
$49.5M
$24.2M 0.4%
+6,710,429
New +$21.7M
PODD icon
41
Insulet
PODD
$11.4B
$22.7M 0.38%
112,433
+2,372
+2% +$427K
NKTX icon
42
Nkarta
NKTX
$186M
$22.5M 0.37%
3,799,143
-1,394,944
-27% -$9.87M
DCGO icon
43
DocGo
DCGO
$64.3M
$22.2M 0.37%
7,195,956
+2,091,569
+41% +$6.89M
INMD icon
44
InMode
INMD
$889M
$21.3M 0.35%
1,166,704
– –
PACS icon
45
PACS Group
PACS
$7.3B
$19.6M 0.33%
+663,851
New +$18.1M
LNTH icon
46
Lantheus
LNTH
$7B
$19.3M 0.32%
240,218
+31
+0% +$2.27K
CSTL icon
47
Castle Biosciences
CSTL
$733M
$19M 0.32%
874,609
-53,408
-6% -$1.19M
NAMS icon
48
NewAmsterdam Pharma
NAMS
$3.7B
$16.7M 0.28%
869,250
+202,250
+30% +$4.06M
PRLD icon
49
Prelude Therapeutics
PRLD
$335M
$15.7M 0.26%
4,133,000
– –
KYTX icon
50
Kyverna Therapeutics
KYTX
$453M
$14.9M 0.25%
1,983,000
+520,663
+36% +$7.95M
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2024 Portfolio in Review

As of Q2 2024, Deerfield Management held 592 positions worth $6.01B, up 4.6% from $5.75B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q2 2024 filing shows 224 new, 125 increased, 42 reduced and 159 closed positions. Its largest new stake was Waystar Holding Corp: 4,952,004 shares worth $106M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q2 2024 buy was Waystar Holding Corp: 4,952,004 shares worth $106M.
  • Deerfield Management added most to Baxter International in Q2 2024, an estimated $57.9M increase.
  • Deerfield Management's biggest Q2 2024 reduction was Oscar Health, cutting an estimated $44.4M.
  • Deerfield Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $136M.
  • Deerfield Management's ten largest holdings make up 52% of its $6.01B portfolio in Q2 2024.
  • Deerfield Management opened 224 new positions and closed 159 in Q2 2024.
  • Deerfield Management's portfolio value rose 4.6% quarter-over-quarter to $6.01B.

Based on Deerfield Management's 13F filing for Q2 2024, filed 14 Aug 2024.